Rush University researcher recognized for longitudinal studies on aging, memory, and dementia.
Researchers report a link between sleepiness and accelerated Aβ buildup in the cingulate and precuneus of elderly adults without dementia.
Voyager Therapeutics announced positive interim results from a small, ongoing Phase 1b trial in people with advanced PD.
Representing each cell as a point, the atlas could help scientists measure brain-wide cell numbers and activity in health and disease.
Two new papers strengthen the evidence that TREM2 protects against amyloid pathology.
A winter storm cut the meeting short, but not before attendees learned that viral load correlates with clinical and pathological traits of AD.
A CRISPR knockout screen in human cells and mouse neurons found genes that tweak C9ORF72 toxicity, zeroing in on ER stress as a potential therapeutic target.
After verubecestat’s demise, scientists ask if BACE inhibitor side effects could partly stem from the other BACE.
In transgenic mice, killing off microglia with the CSF1R inhibitor PLX3397 prevented accumulation of intraneuronal Aβ, neuritic plaques.
World’s biggest brain research award goes to European leaders on Aβ tau and TREM2.
In three independent cohorts, cognitively healthy people had a higher amyloid burden as they approached the age at which their parents developed late-onset AD.
When neurons stop making mutant TDP-43, microglia alter their transcription profiles, clear aggregates, and help restore motor function.
Ionis Pharmaceuticals reported positive top-line data from the Phase 1/2a trial of its ASO.
Scientists found FUS interacts with Argonaute, miRNAs, and targets mRNAs to quell gene expression.
In neuronal cell culture, extracts from AD mouse brain seeded intracellular clumps of Aβ oligomers. Like prions, the inclusions persisted through generations of cells.